Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.5444
-0.0514-8.63%
Post-market: 0.55000.0056+1.03%19:58 EDT
Volume:1.12M
Turnover:624.20K
Market Cap:71.32M
PE:-1.69
High:0.6053
Open:0.6000
Low:0.5418
Close:0.5958
52wk High:1.36
52wk Low:0.5418
Shares:131.00M
Float Shares:126.58M
Volume Ratio:1.18
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3215
EPS(LYR):-0.3000
ROE:-10187.64%
ROA:-211.24%
PB:-11.56
PE(LYR):-1.81

Loading ...

Oncolytics announces publication of data on pelareorep in liver cancer

TIPRANKS
·
Sep 29

Oncolytics Biotech Says Study Shows Pelareorep Triggers Immune Activation in Liver Cancer, Boosting Immunotherapy Sensitivity

Reuters
·
Sep 29

Oncolytics reports accelerating enrollment in REO 033 study

TIPRANKS
·
Sep 28

Oncolytics Biotech - Expects Interim Part a Clinical Update by Year-End 2026

THOMSON REUTERS
·
Sep 28

Oncolytics Biotech® Reports Accelerating Enrollment in Randomized Reo 033 Ras-Mutant, Mss Colorectal Cancer Study

THOMSON REUTERS
·
Sep 28

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Sep 28

Oncolytics Biotech (ONCY) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 22

Oncolytics Reports Positive Preclinical Data Combining Pelareorep with Pan-RAS Inhibitor in Colorectal Cancer Model

Reuters
·
Sep 10

Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-Ras Inhibitor in Colorectal Cancer

THOMSON REUTERS
·
Sep 10

Oncolytics Biotech Inc. : H.c. Wainwright Cuts Target Price to $5 from $10

THOMSON REUTERS
·
Aug 19

U.S. Research Roundup-Cogent Communications, Dollar Tree, Home Depot

Reuters
·
Aug 19

Oncolytics aligns with FDA on path for REO 033 expansion study

TIPRANKS
·
Aug 18

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line Ras-Mutant Mss Colorectal Cancer

THOMSON REUTERS
·
Aug 18

Oncolytics Biotech - Receives FDA Feedback on Pivotal Part B Expansion of Reo 033

THOMSON REUTERS
·
Aug 18

Oncolytics Says FDA Aligns on Pivotal Expansion Path for REO 033 Colorectal Cancer Trial

Reuters
·
Aug 18

Oncolytics Net Loss Widens to $9.44 Million in Q2 2026; R&D Expenses More than Doubled to $4.26 Million

Reuters
·
Aug 13

Oncolytics Biotech Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule

Reuters
·
Jul 25

Oncolytics Biotech Announces Press Release Available

Reuters
·
Jul 20

Oncolytics Biotech Wins FDA Fast Track Status for Pelareorep in Second-line Anal Cancer

Reuters
·
Jul 20

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-line and Later Anal Cancer

THOMSON REUTERS
·
Jul 20